Accretion/Dilution Analysis, Explained
Accretion and dilution measure one narrow thing: whether a deal raises or lowers the acquirer's earnings per share. Here is the pro-forma EPS math, what drives the result, and why it isn't the same question as whether the deal is a good idea.
What accretion and dilution mean
Accretion/dilution analysis asks one narrow question about an acquisition: does it raise or lower the acquirer's earnings per share? If pro-forma (combined) EPS ends up higher than the acquirer's standalone EPS, the deal is accretive. If it ends up lower, the deal is dilutive. It is a mechanical, purely accounting-driven question, deliberately separate from whether the deal is actually a good use of the acquirer's capital.
Interviewers ask about it constantly because it is the standard first-pass framework for evaluating a stock deal, and because the mechanics reward the same discipline a DCF does: knowing exactly what belongs in the numerator and denominator, and why.
The formula: pro-forma EPS
The numerator combines both companies' net income (before any deal-specific adjustments like new interest expense or foregone interest on cash used, which a fuller model would layer in). The denominator is the acquirer's existing share count plus whatever new shares it issues to pay for the deal, in an all-stock transaction. Compare that pro-forma figure to the acquirer's standalone EPS before the deal:
A positive result is accretive, a negative result is dilutive.
Worked example: an acquirer earns $400mm of net income on 100mm shares (a $4.00 standalone EPS), and buys a target earning $200mm of net income by issuing 20mm new shares.
Accretion = $5.00 − $4.00 = +$1.00, accretive
What drives accretion in an all-stock deal
In a pure stock-for-stock deal, whether the transaction is accretive comes down to a comparison of P/E multiples. If the acquirer trades at a higher P/E than the effective P/E it is paying for the target, the deal tends to be accretive: the acquirer is issuing relatively expensive stock (low earnings yield) to buy relatively cheap earnings (high earnings yield). If the acquirer is paying a higher P/E for the target than its own, the deal tends to be dilutive.
The same logic extends to cash- or debt-funded deals, just with a different comparison: instead of the acquirer's own P/E, compare the target's earnings yield (net income divided by purchase price, the inverse of the P/E paid) to the after-tax cost of the financing used, whether that is the after-tax cost of new debt or the foregone after-tax interest on cash that is spent instead of invested. If the target's earnings yield is higher than that financing cost, the deal tends to be accretive.
Why accretion is not the same thing as value creation
Accretion/dilution is a mechanical EPS calculation, not a verdict on whether a deal creates value. A deal can be accretive simply because the acquirer overpaid using extremely cheap stock or debt, while still destroying value if the price paid exceeds what the target is actually worth (for instance, more than its DCF value). Conversely, a dilutive deal can still create real value if the target is a strong strategic fit purchased at a fair price, with EPS simply taking a temporary hit before synergies phase in.
For that reason, accretion/dilution is best treated as one useful, easy-to-communicate data point among several, alongside a proper valuation of the target and an honest view of the deal's strategic rationale, rather than the actual test of whether to do the deal.
Try a real question
This is the same question engine and thirty-second clock a real duel uses, filtered to this guide's topic. No account, no signup, nothing saved.
Common interview questions
What does it mean for an acquisition to be accretive?
It means the acquirer's pro-forma (post-deal, combined) earnings per share is higher than its standalone EPS before the deal. Dilutive is the opposite: pro-forma EPS ends up lower than standalone EPS.
How do you calculate pro-forma EPS for a stock deal?
Add the acquirer's and target's net income together, then divide by the acquirer's original share count plus the new shares issued to fund the deal. Compare that figure to the acquirer's standalone EPS: a higher pro-forma number is accretive, a lower one is dilutive.
Why is an all-stock deal accretive when the acquirer's P/E is higher than the target's?
A higher P/E means the acquirer's stock has a lower earnings yield (earnings per dollar of value), so each share of relatively expensive acquirer stock issued buys a larger amount of the target's relatively cheap earnings. That's what mechanically pushes combined EPS above the acquirer's standalone EPS.
Does an accretive deal automatically mean it created shareholder value?
No. Accretion/dilution is a mechanical earnings-per-share calculation, not a valuation verdict. A deal can be accretive purely because financing was cheap while still being a bad deal if the acquirer overpaid relative to the target's actual worth, and a dilutive deal can still be value-creating if the strategic logic and price are sound.
How does financing a deal with cash or debt change the accretion/dilution math?
Instead of comparing P/E multiples, compare the target's earnings yield (net income divided by the price paid) to the after-tax cost of whatever is funding the deal: the after-tax cost of new debt, or the after-tax interest given up on cash that's spent instead of invested. If the target's earnings yield is higher than that financing cost, the deal tends to be accretive.
What items does a full accretion/dilution model add that a quick pro-forma EPS calculation leaves out?
A complete model layers in deal-specific adjustments the basic formula skips: incremental interest expense on new acquisition debt, foregone interest income on cash used, amortization of any new intangible assets created in the deal, and the associated tax effects of each. These can meaningfully shift the result away from the simplified combined-net-income calculation.